Effects of platelet inhibitors on propyl gallate-induced platelet aggregation, protein tyrosine phosphorylation, and platelet factor 3 activation

Blood Coagulation and Fibrinolysis

Volumn 15, Issue 3, 2004, Pages 199-206

  Xiao, Hongyan ^a   Kovics, Richard ^b   Jackson, Van ^b   Remick, Daniel G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Annexin V; Coagulation; Flow cytometry; Platelet activation; Platelet aggregation; Platelet factor 3; Propyl gallate; Thrombosis; Tyrosine phosphorylation; Western blot

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE PHOSPHATE; ADENOSINE PHOSPHATE RECEPTOR; ANTITHROMBOCYTIC AGENT; APYRASE; CYCLOOXYGENASE 1; CYTOSKELETON PROTEIN; FIBRINOGEN RECEPTOR; GALLIC ACID PROPYL ESTER; LIPOCORTIN 5; PHOSPHATIDYLSERINE; PROTEIN KINASE P60; RECEPTOR; THROMBOCYTE FACTOR 3; TYROSINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING ASSAY; BLOOD CLOTTING; BLOOD CLOTTING TIME; CELL STIMULATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THROMBOCYTE; THROMBOCYTE AGGREGATION;

ANNEXIN A5; ANTIOXIDANTS; APYRASE; ASPIRIN; HUMANS; PHOSPHORYLATION; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FACTOR 3; PROPYL GALLATE; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS PP60(C-SRC);

EID: 2342419604     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200404000-00001     Document Type: Article

References (43)

1. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 1975; 72:2294-2298.
2. Fitzgerald GA. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991; 68:11B-15B.
3. Gaardner A, Jonsen J, Laland S, Hellem A, Owen PA. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961; 192:531-532.
4. Born GVR. Adenosine diphosphate as a mediator of platelet aggregation in vivo: an editorial point of view. Circulation 1985; 72:741-742.
5. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation, I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998; 273:2024-2029.
6. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation, II. The P2y1 receptor mediates ADP-induced intra cellular calcium mobilization and shape change in platelets. J Biol Chem 1998; 273:2030-2034.
7. Geiger J, Honig-Liedl P, Schanzenbacher P, Walter U. Ligand specificity and ticlopidine effects distinguish three platelet ADP receptors. Eur J Pharmacol 1998; 351:235-246.
8. Savi P, Beuvarger P, Labouret C, Delfaud M, Salel V, Kaghad M, Herbert JM. Role of P2Y1 purinoceptor in ADP-induced platelet activation. FEBS Lett 1998; 422:291-295.
9. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998; 95:8070-8074.
10. Hechler B, Leon C, Vial P, Frelin C, Cazenave JP, Gachet C. The P2Y1 receptor is necessary for adenosine 5′-diphosphate-induced platelet aggregation. Blood 1998; 92:152-159.
11. Fagura MS, Dainty IA, McKay GD, Kirk IP, Humphries RG, Robertson MJ, et al. P2Y1-receptors in human platelets which are pharmacologically distinct from P2Y (ADP)-receptors. Br J Pharmacol 1998; 124:157-164.
12. Kunapuli SP, Daniel JL. P2 receptor subtypes in the cardiovascular system. Biochem J 1998; 336:513-523.
13. Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood 1988; 71:831-843.
14. Golden A, Brugge JS, Shattil SJ. Role of platelet membrane glycoprotein IIb/IIIa in agonist-induced tyrosine phosphorylation of platelet proteins. J Cell Biol 1990; 111:3117-3127.
15. Kieffer N, Fitzgerald LA, Wolf D, Cheresh DA, Phillips DR. Adhesive properties of the beta 3 integrins: comparison of GP IIb/IIIa and the vitronectin receptor individually expressed in human melanoma cells. J Cell Biol 1991; 113:451-461.
16. Gawaz MP, Loftus JC, Bajt ML, Frojmovic MM, Plow EF, Ginsberg MH. Ligand bridging mediates integrin alpha IIb beta 3 (platelet GP IIB/IIIA) dependent homotypic and heterotypic cell-cell interactions. J Clin Invest 1991; 88:1128-1134.
17. Phillips DR, Charo IF, Scarborough RM. GPIIb/IIIa: the responsive integrin. Cell 1991; 65:359-362.
18. Byzova TV, Plow EF. Networking in the hemostatic system. Integrin alpha II beta 3 binds prothrombin and influences its activation. J Biol Chem 1997; 272:27183-27188.
19. a forming activity and platelet factor 3 activity and their relationship to platelet aggregation and secretion. Br J Haematol 1978; 40:311-331.
20. Sandberg H, Anderson L-O, Hoglund S. Isolation and characterization of lipid-protein particles containing platelet factor 3 released from platelets. Biochem J 1982; 203:303-311.
21. Bode AP, Dombrose FA, Lentz BR. Differentiation of factor V-like coagulant activity from catalytic phospholipid-like surface activity in membrane fractions derived from human platelets. Thromb Res 1981; 22:603-621.
22. a with platelets. J Biol Chem 1982; 254:3963-3969.
23. Xiao HY, Siddiqui RA, Mohammed AL-H, Sliva D, Kovacs R. Phospholipids released from activated platelets improve platelet aggregation and endothelial cell migration. Platelets 2001; 12:1-9.
24. Speck RE, inventor. Analytical Control System, Inc., assignee. Substance relating to testing of blood coagulation. United States Patent 3 486981, 15 March 1969.
25. Speck RE. An accurate assay for platelet factor 3. Am Clin Lab 1993; 12:16-18.
26. Speck RE. Comparison of slide platelet aggregation reagents. Am Clin Lab 1994; 13:22-23.
27. Speck RE. Initial screen for abnormal platelet condition. United States Patent 5 569 590, 29 October 1996.
28. Petrzelova A, Stejskal D, Proskova J, Oral I, Dostalova S, Lacnak B, et al. Initial experience with use of cationic propyl gallate as an inducer of thrombocyte aggregation in evaluation of anti-aggregation therapy. Vnitrni Lekarstvi 2001; 47:747-752.
29. Xiao H, Jepkorir CJ, Harvey K, Remick DG. Thrombin-induced platelet microparticles improved the aggregability of cryopreserved platelets. Cryobiology 2002; 44:179-188.
30. Xiao HY, Matsubayashi H, Bonderman DP, Bonderman PW, Reid T, Miraglia CC, Gao DY. Generation of annexin V-positive platelets and shedding of microparticles with stimulus-dependent procoagulant activity during storage of platelets at 4°C. Transfusion 2000; 40:420-427.
31. Qi SP, Hu PR. Effect of the esters of gallic acid on model and human blood platelet membranes studied by Fourier transform infrared spectroscopy. Sci China B, Chem Life Sci Earth Sci 1993; 36:702-709.
32. Michelson AD. Platelet activation by thrombin can be directly measured in whole blood through the use of peptide GPRP and flow cytometry: methods and clinical applications. Blood Coagul Fibrinolysis 1994; 5:121-131.
33. Smith WL. Prostanoid biosynthesis and the mechanism of action. Am J Physiol 1992; 263:F118-F191.
34. Shattil SJ, Kashiwagi H, Pampori N. Integrin signaling: the platelet paradigm. Blood 1998; 91:2645-2657.
35. Rosa JP, Artcanuthurry V, Grelac F, Maclouf J, Caen JP, Levy-Toledano S. Reassessment of protein tyrosine phosphorylation in thrombasthenic platelets: evidence that phosphorylation of cortactin and a 64 kDa protein is dependent on thrombin activation and integrin αIIbβ3. Blood 1997; 89:4385-4392.
36. Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12:430-436.
37. Ezumi Y, Shindoh K, Tsuji M, Takayama H. Physical and functional association of src family kinase Fyn and Lyn with the collegen receptor glycoprotein VI-Fc receptor γ-chain complex on human platelets. J Exp Med 1998; 188:267-276.
38. Ware AJ, Coller BS. Platelet morphology, biochemistry and function. In: Beutler E, Lichtman MA, Coller BS, Kipps TJ (editors): Hematology. New York: McGraw Hill; 1995, pp. 1161-1201.
39. Fox JEB, Lipfert L, Clark EA, Reynold CC, Austin CD, Brugge JS. On the role of the platelet membrane skeleton in mediating signal transduction: association of GPIIb/IIIa, pp60 sup c-src, pp62 sup c-yes, and the p21 sup ras GTPase-activating protein with the membrane skeleton. J Biol Chem 1993; 268:25973-25984.
40. Bachelot C, Cano E, Grelac F, Saleum S, Druker BJ, Levy-Toledano S, et al. Functional implications of tyrosine protein phosphorylation in platelets. Simutaneous studies with different agonists and inhibitors. Biochem J 1992; 284:923-928.
41. Ozaki Y, Satoh K, Yatomi Y, Miura S, Fujimura Y, Kume S. Protein tyrosine phosphorylation in human platelets induced by interaction between glycoprotein Ib and von Willebrand factor. Biochim Biophys Acta 1995; 1243:482-488.
42. Nurden P, Poujol C, Durrieu-Jais C, Winckler J, Combrie R, Macchi L, et al. Labeling of the internal pool of GPIIb-IIIa in platelets by c7E3 Fab fragments (abciximab): flow and endocyticmechanisms contribute to the transport. Blood 1999; 93:1622-1633.
43. Bihour C, Durrieu-Jais C, Machi L, Poujol C, Coste P, Besse P, et al. Expression of markers of platelet activation and interpatient variation in response to abciximab. Arterioscler Thromb Vasc Biol 1999; 93:1622-1633.